We are live on ! Find out more
FIS

FCPM III Services Portfolio holdings

AUM $722M
1-Year Est. Return 73.61%
This Fund
S&P 500
This Quarter Est. Return
+0.76%
1 Year Est. Return
+73.61%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$339M
AUM Growth
Cap. Flow
+$307M
Cap. Flow %
90.31%
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.47B
$132M 38.94%
+11,831,461
New +$108M
DYN icon
2
Dyne Therapeutics
DYN
$3.88B
$81.5M 24.03%
+6,131,079
New +$59.9M
ENGN icon
3
enGene Therapeutics
ENGN
$125M
$80.1M 23.6%
+8,677,951
New +$76.8M
REPL icon
4
Replimune Group
REPL
$882M
$41M 12.09%
+4,866,499
New +$56.4M
ENGNW icon
5
enGene Therapeutics Warrants
ENGNW
$3.53M
$2.45M 0.72%
+3,878,148
New +$2.98M
ACHL
6
DELISTED
Achilles Therapeutics
ACHL
$2.13M 0.63%
+2,390,050
New +$2.05M

Similar funds

FCPM III Services's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for FCPM III Services, which disclosed 6 positions worth $339M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is NewAmsterdam Pharma: 11,831,461 shares worth $132M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets.

  • FCPM III Services's largest Q4 2023 buy was NewAmsterdam Pharma: 11,831,461 shares worth $132M.
  • FCPM III Services's ten largest holdings make up 100% of its $339M portfolio in Q4 2023.
  • FCPM III Services disclosed 6 positions in Q4 2023, its first 13F filing on record.

Based on FCPM III Services's 13F filing for Q4 2023, filed 7 Mar 2024.